Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Published

on

–News Direct–

By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.

Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.

Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.

Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.

Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.

CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.

Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.

CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).

When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:

1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;

2) Favorable changes in the trajectory of tumor progression;

3) Decreased tumor size of target lesions in most patients; and

4) Reduced size of uninjected tumor lesions.

The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.

As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.

When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.

In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.

In the upcoming year, Candel plans to announce data readouts for the following:

1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;

2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;

3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267

Candel Therapeutics

comtex tracking

COMTEX_453480918/2655/2024-06-07T08:28:02

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Vitalismo Launches Lifelike Artificial Cedar and Olive Trees, Creating Evergreen Spaces with Ease

Published

on

New UV-Resistant, Zero-Maintenance Plants Deliver Year-Round Greenery for Homes, Offices, and Outdoor Spaces

CHARLOTTE, NC, United States, 18th Jun 2026 – Vitalismo, a brand specializing in high-quality lifelike artificial plants, has officially expanded its Amazon product lineup with two new decorative tree collections: artificial cedar topiary and artificial olive tree. Designed for both residential and commercial environments, the new additions reflect the growing demand for low-maintenance greenery solutions that combine aesthetics, convenience, and long-term durability.

Vitalismo’s Mission: Vibrant Spaces, Minimal Effort

As consumer interest in nature-inspired interiors continues to rise, artificial plants are becoming an increasingly popular choice for homes, offices, hospitality venues, and retail spaces. Unlike live plants, artificial greenery requires no watering, pruning, fertilizing, or specialized lighting conditions, while maintaining a consistent appearance throughout the year. Advances in simulation craftsmanship and weather-resistant materials have further accelerated adoption of large decorative artificial trees, including olive and cedar varieties, across a wide range of indoor and outdoor settings.

“More consumers today are seeking home décor solutions that balance beauty with convenience,” said a spokesperson for Vitalismo. “Through realistic, low-maintenance artificial plants, we aim to help people create welcoming green spaces that remain vibrant year-round while reducing the effort typically associated with plant care.” 

Vitalismo was founded with a simple mission: to help consumers create vibrant, evergreen spaces without the time and resources traditionally required for plant care.

Artificial Cedar and Olive Tree Collections Built Around Evergreen Beauty

Vitalismo’s latest Amazon launches address this trend directly, offering two distinct tree styles that combine detailed craftsmanship with long-term durability and no upkeep requirements.

The Vitalismo Artificial Topiary Cedar Trees are available in five size options, ranging from 2 feet to 6 feet tall. The artificial topiary cedar tree is constructed from high-quality PE material and plastic, with branches and leaves engineered using simulation technology to reproduce the natural layered growth pattern of a cedar tree. The leaves feature clearly defined textures, along with newly designed buds that enhance the sense of organic growth.

A key functional feature is the flexibility of the branches: each unit allows users to bend and reshape the foliage to suit the dimensions and layout of the intended space. This makes the cedar topiary adaptable to narrow entryways, covered patios, balconies, and front porch placements equally well. The trees are odorless, weather-tolerant, and carry a UV-resistant treatment that prevents color fading from prolonged sun exposure, making them suitable for semi-exposed outdoor use as well as indoor display.

Most recently, Vitalismo introduced the Artificial Indoor Olive Trees, which are available in four size options, spanning 5 feet to 8 feet in height. Depending on the size selected, individual units feature between 641 and 1530 meticulously crafted leaves with clear textures, and include decorative artificial olive fruits. 

Each unit ships pre-assembled in a heavy-duty pot constructed from durable plastic and concrete for superior stability, and includes a white round planter. The collection has received multiple industry recognitions, including the MUSE Design Awards, American Good Design Award, and Gold Award distinctions, highlighting its realistic appearance, craftsmanship, and decorative versatility.

Looking Ahead

Looking ahead, Vitalismo remains committed to innovation and sustainability, focusing on creating realistic, high-quality artificial plants that bring vibrant greenery to homes, offices, and commercial spaces year-round. The brand plans to continue developing increasingly lifelike and premium products to provide consumers with the experience of a flourishing natural environment without the challenges of traditional plant care. 

At the same time, Vitalismo aims to explore more environmentally friendly and durable materials to extend product longevity and reduce resource waste associated with frequent replacements. The company also intends to expand its artificial plant collections to cater to a wider range of decorative needs across different spaces. 

Both the Vitalismo Artificial Topiary Cedar Trees and the Artificial Indoor Olive Trees are currently available on Amazon, with multiple size options listed on each product page. 

Learn more information through Vitalismo Amazon store.

ABOUT VITALISMO

Vitalismo is a brand specializing in high-quality, lifelike artificial plants, dedicated to providing maintenance-free, evergreen decorative solutions for homes and offices. All Vitalismo products feature UV-resistant and fade-resistant finishes, offering a realistic appearance across every product line. The brand’s plants are non-toxic and safe for households with pets and children, making them a practical choice for a wide range of customers.

Media Contact

Organization: Vitalismo

Contact Person: Bojie Wu

Website: https://www.amazon.com/Artificial-Planter-Full-Shape-Premium-Plastic/dp/B0GQYF5DK5

Email:
support@vitalismo.shop

City: CHARLOTTE

State: NC

Country:United States

Release id:46217

The post Vitalismo Launches Lifelike Artificial Cedar and Olive Trees, Creating Evergreen Spaces with Ease appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CJ William 2026 Luxury Watch Resale Report Patek Leads as Cartier Emerges Value Play

Published

on

CJ William, a Surfside, Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report. The annual analysis combines public secondary-market indices with dealer transaction activity, finding that Patek Philippe led major brands in 2025 and that select Cartier references quietly outperformed the broader market.

SURFSIDE, Fla. – CJ William, a South Florida luxury watch and Hermes dealer, today released its 2026 Luxury Watch Resale Report, an annual analysis of which timepieces held, gained, or lost value across the secondary market over the past year.

The headline finding: luxury watch resale value turned a corner in 2025. After roughly two years of decline, prices stabilized and the strongest references posted real gains. Patek Philippe led all major brands at about 7.7 percent for the year, driven by the Aquanaut and Nautilus, while Rolex stabilized and Audemars Piguet returned to growth. The report also flags a less obvious trend: select Cartier references outperformed the broader market even as headline hype models cooled.

“Everyone watches the Daytona and the Nautilus, and they should, because top-tier Patek, Rolex, Audemars Piguet and Richard Mille continue to hold and in many cases grow their value,” said Eitan Cohen, founder of CJ William. “But the buyers walking into our Surfside showroom in 2026 are asking smarter questions about value, and brands like Cartier are rewarding them.”

“The white-dial Daytona Panda is the single most-requested watch on our desk right now,” Cohen added. “Steel sports Rolex, the Nautilus and the Aquanaut move fast in South Florida, and Cartier prices have quietly climbed even as demand held steady.”

Key findings from the 2026 report include the top 10 references by value retention over the past year, the brands that recovered fastest after the market correction, where value is hiding in 2026, and a South Florida market cut showing which models move fastest in Miami, Surfside and Bal Harbour.

CJ William compiled the report from leading public secondary-market indices combined with its own buying and selling activity, giving a dealer-side view of real demand rather than listing prices alone.

The full report is available at https://cjwilliam.com/wholesale/luxury-watch-resale-value-report-2026/.

CJ William buys and sells Rolex, Patek Philippe, Audemars Piguet, Richard Mille, Cartier and other luxury watches, with in-house New York authentication, an 18-month warranty and fully insured FedEx overnight shipping. The firm makes same-day offers and welcomes in-person appointments at its Surfside showroom.

About CJ William

CJ William is a luxury watch, Hermes and antique silver dealer at 9573 Harding Avenue, Surfside, FL 33154. The showroom buys, sells and sources luxury timepieces and offers corporate gifting nationwide. Invoicing entity: David and Sons Watches LLC.

Media Contact
CJ William
Email: e@cjwilliam.com
Phone: (347) 510-0668
Website: cjwilliam.com

Media Contact

Organization: CJ William

Contact Person: Eitan Cohen

Website: https://cjwilliam.com/wholesale/luxury-watch-resale-value-report-2026/

Email:
e@cjwilliam.com

Contact Number: +13475100668

Address:9573 Harding Avenue

City: Surfside

State: Florida

Country:United States

Release id:46247

The post CJ William 2026 Luxury Watch Resale Report Patek Leads as Cartier Emerges Value Play appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Scientology Volunteers Bring Drug Prevention Education to Clondalkin Festival in Ireland

Published

on

At a family-focused community festival in west Dublin, volunteers from the Scientology Community Centre Dublin shared “Truth About Drugs” educational materials and held conversations on prevention, resilience and community responsibility.

Brussels, Belgium, 18th Jun 2026 — Volunteers from the Scientology Community Centre Dublin took part in the Clondalkin Festival in west Dublin, bringing drug-prevention education to a public community setting through the Truth About Drugs initiative, a campaign supported internationally by Scientologists and community volunteers.

Scientology Volunteers Bring Drug-Prevention Education to Clondalkin Festival in Ireland

The outreach, held during the local festival in Clondalkin, included an information tent, educational displays and free drug-prevention booklets made available to families, young people and local residents attending the event. Photographs from the day show volunteers speaking with members of the public, parents, young adults and local service personnel in a busy festival environment marked by family activities, civic engagement and summer weather.

The Scientology Community Centre Dublin described the day as “brilliant,” noting that although the subject of drugs is not an easy one, the conversations held during the festival included “hope, resilience and kindness.” The centre also publicly thanked the volunteers who helped make the outreach possible.

The initiative formed part of the broader drug-prevention programme supported by the Church of Scientology, developed to provide factual, plain-language information about commonly used substances and their effects. The materials are widely used by volunteers, educators and community groups as prevention tools in schools, neighbourhoods and public events. The campaign’s emphasis is educational rather than punitive: to place understandable information in people’s hands before harm occurs.

At the Clondalkin Festival, the Drug-Free World tent created a space where residents could approach the subject informally. Booklets were displayed on substances including cannabis, cocaine, alcohol, synthetic drugs and prescription drug abuse, while volunteers spoke with visitors about the importance of early prevention, informed choices and community awareness. One photograph from the event shows children signing a pledge board, while others show adults reviewing materials and asking questions at the stand.

The participation of the Scientology Community Centre Dublin reflects a wider pattern of local social-betterment activities carried out by Scientology churches, missions and affiliated groups across Europe. In Ireland, the Dublin centre has hosted and supported community initiatives ranging from volunteer recognition to educational events, interfaith meetings and social outreach. In this case, the focus was on drug prevention in a public festival setting where families and young people were already gathered.

The Foundation for a Drug-Free World works through secular educational resources, public service announcements and booklets designed to communicate the effects of drugs in accessible language. The campaign has been supported by members of the Church of Scientology as one of several humanitarian initiatives inspired by the work of L. Ron Hubbard, who placed emphasis on education, personal responsibility and practical help to improve social conditions.

The subject remains significant in Ireland and across Europe, where public authorities, educators and community organisations continue to address the social consequences of drug use, addiction, exploitation and youth vulnerability. Community-based prevention efforts, particularly those that reach families in ordinary public spaces, are often viewed as one element in a wider response that also includes health services, law enforcement, education and social support.

For volunteers at the Clondalkin Festival, the central aim was to make information available in a non-confrontational setting. The images from the event show a range of conversations: a volunteer explaining materials to a visitor, others speaking with public safety personnel, and families passing by the stand during the festival. The visible presence of children and parents at the event underlined the importance of prevention being addressed before problems become entrenched.

Ivan Arjona, representative of the Church of Scientology to the European Union, the OSCE, the Council of Europe and the United Nations, said the Clondalkin outreach reflected the kind of civic responsibility that strengthens communities.

Drug-prevention education is most effective when it is brought close to people, in places where families, young people and neighbours already meet,” Arjona said. “What took place in Clondalkin is a simple but meaningful example of European civic values in practice: people volunteering their time, speaking respectfully about difficult subjects, and helping others with information that can protect lives and futures.

Arjona added that community initiatives of this kind should be understood as part of a broader culture of prevention. “Across Europe, public institutions cannot carry every social burden alone. Civil society, faith communities, educators, parents and volunteers all have a role to play. When this is done with respect, factual information and care for human dignity, it contributes to healthier and more resilient communities.

The Church of Scientology traces its social-betterment work to the writings and initiatives of L. Ron Hubbard, whose works inspired programmes in drug prevention, human rights education, literacy, disaster response and moral education. In the case of drug prevention, Scientology churches and volunteers support the dissemination of factual materials intended for use by people of any background, without regard to religious belief.

The Clondalkin Festival outreach also illustrates how local religious and community organisations can contribute to public life without making the activity the subject of religious instruction. The visible focus of the stand was educational: booklets, displays, conversations and information. In that sense, the initiative was consistent with many European models of community service, where faith-inspired organisations participate in civic spaces through practical social programmes.

The Dublin volunteers’ participation in the festival placed the campaign in a real-life setting: a local street, families moving between festival attractions, parents with children, local services nearby and residents taking a few minutes to discuss a subject that affects communities across social and economic lines. The tone of the outreach, as reflected in the centre’s public statement, was not alarmist but constructive, centred on hope, resilience and kindness.

The Church of Scientology, its churches, missions, groups and members are present across the European continent. Scientology Europe reports a continent-wide presence through more than 140 churches, missions and affiliated groups in at least 27 European nations, alongside thousands of community-based social betterment and reform initiatives focused on education, prevention and neighbourhood-level support, inspired by the work of Scientology founder L. Ron Hubbard.

Within Europe’s diverse national frameworks for religion, the Church’s recognitions continue to expand, with administrative and judicial authorities in Spain, Portugal, Sweden, the Netherlands, Italy, Germany Slovakia and others, as well as the European Court of Human Rights, having addressed and acknowledged Scientology communities as protected by the national and international provisions of Freedom of Religion or belief.

Media Contact

Organization: European Office Church of Scientology for Public Affairs and Human Rights

Contact Person: Ivan Arjona

Website: https://www.scientologyeurope.org

Email: Send Email

Address:Boulevard de Waterloo 103

City: Brussels

State: Brussels

Country:Belgium

Release id:46227

The post Scientology Volunteers Bring Drug Prevention Education to Clondalkin Festival in Ireland appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST